However, since SGLT2 inhibitors are a promising option in T2D treatment, it is of great importance to further target their pharmacogenetic aspects using properly-sized cohorts with adequate study designs [21]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.